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ABSTRACT
Maintenance use of short-acting adrenergic agents can
cause tachyphylaxis, increased non-specific bronchial
hyperreactivity, poorer clinical control, a worsened late
allergic reaction and possibly an increased risk of
death; therefore, ‘as needed’ use is preferable. The
choice of a first line anti-inflammatory drug, between
inhaled corticosteroids and non-steroidal drugs (cro-
molyn sodium or nedocromil sodium), has to be made
considering their risk–benefit ratio. Although in severe
patients the efficacy of inhaled corticosteroids is clearly
superior to that of cromolyn, in mild-to-moderate
patients the efficacy is comparable. In terms of safety,
non-steroidal drugs have a better safety profile than
inhaled corticosteroids, which can cause growth sup-
pression even at regular doses, especially in mild-
to-moderate patients. Although some investigators have
raised the possibility of irreversible airway obstruction if
treatment with inhaled corticosteroids is delayed, studies
by my group and others, using non-steroidal drugs as
first line, have not confirmed that suspicion. In conclu-
sion, a step-wise approach in children is still justified,
starting with non-steroidal drugs (cromolyn sodium or
nedocromil sodium) in mild persistent asthma and
using inhaled corticosteroids only in patients poorly
controlled by the non-steroidal drugs.
Key words: cromolyn sodium, inhaled cortico-
steroids, maintenance adrenergic agents, nedocromil
sodium, non-steroidal anti-inflammatory drugs.
INTRODUCTION
Risk/benefit ratios are an important consideration for
every drug. For some drugs used to treat asthma, this
ratio is still very much debated. Short-acting beta-
adrenoreceptor agonists are the most widely used drugs
in asthma and the most valuable tools for treating acute
attacks. The dispute is whether they should be used as
regular (maintenance) therapy or on an ‘as needed’ basis
for symptom relief.
The other major debate is whether inhaled corti-
costeroids or non-steroidal, anti-inflammatory drugs,
such as disodium cromoglycate (DSCG), should be the
first-line anti-inflammatory treatment. This question is
especially debated for children, in whom growth suppres-
sion is a potential side-effect of inhaled corticosteroids.
MAINTENANCE ADRENERGIC AGENTS
Some of the evidence that regular use of adrenergic
agents can have detrimental effects has been known for
some time, because of the tendency of these agents to
cause subsensitivity (tachyphylaxis). There is a slight
reduction in peak bronchodilation and a more severe
reduction in the duration of bronchodilation.1,2 Tachy-
phylaxis occurs also in terms of the bronchoprotective
effect of adrenergic agents. Thus, after 1 week of regular
administration of terbutaline, there is a significant de-
crease in its ability to protect from challenges with both
methacholine and adenosine monophosphate (AMP).3
The next discovery was that regular use of adrenergic
agents can increase non-specific bronchial hyper-
reactivity.4 This is probably not due to subsensitization.5
However, the most clinically relevant evidence came with
the study by Sears and associates showing that regular
administration of fenoterol, compared with ‘as needed’
use, caused not only an increase in bronchial hyper-
reactivity, but also worsened clinical control of asthma.6
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Cockcroft and associates have demonstrated a wors-
ening of the late allergic reaction and increase in
non-specific bronchial reactivity that accompanies the
late allergic reaction in the presence of regular use of
albuterol (Fig. 1).7 In a later study, it was shown that this is
accompanied by an increased eosinophil influx into the
airways.8
One possible explanation for the detrimental effect of
regular use of albuterol is the fact that it is a racemic drug
containing equal proportions of two isomers: R-albuterol,
which causes the bronchodilator effect, and S-albuterol,
which has pro-inflammatory actions.9 Because there 
is disproportionate accumulation of S-albuterol during
regular administration of racemic albuterol, the pro-
inflammatory effect of S-albuterol may predominate.
In some epidemiologic studies, regular use of adrener-
gic agents has been associated with increased risk of
death or near death from asthma.10 A causal relationship
cannot be established from these studies, because 
frequent use of these drugs could simply be a marker 
of more severe asthma. However, use of inhaled corti-
costeroids or oral corticosteroids, which are also markers
of severe asthma, was not associated with increased risk
of death.
One possible explanation for the association with
increased risks of death from asthma is found in a study
by Bel and associates.11 They have shown that pretreat-
ment with albuterol before a histamine or methacholine
challenge test gives initial protection against the lower
doses of these agents. However, when larger doses 
are reached, there is a very steep fall in forced expira-
tory volume in 1 s (FEV1). If this occurs with naturally
occurring triggers, it could explain a life-threatening
bronchospastic event.
Not all studies that have compared regular versus ‘as
needed’ use of adrenergic agents have shown worsened
clinical control on regular use. In some studies, clinical
control was equally good12 or even slightly better on
regular administration.13–15 However, the total number of
doses of adrenergic agents per day needed to give this
degree of control was 2–3-fold greater in the regular
regime than in the ‘as needed’ one; hardly a good argu-
ment for regular use.
It is clear that maintenance therapy with short-acting
beta-adrenoreceptor agonists can have some detrimental
effects and, considering their lack of anti-inflammatory
effects, this type of treatment should be used only if very
aggressive anti-inflammatory treatment fails to control the
symptoms.
FIRST-LINE ANTI-INFLAMMATORY DRUGS
Another major debate is whether inhaled corti-
costeroids or non-steroidal anti-inflammatory drugs, such
as DSCG, should be used as first-line anti-inflammatory
treatments.
The earlier asthma Guidelines16 recommended the
start of anti-inflammatory treatment in moderately severe
patients, defined as having symptoms on more than 
3 days per week. In children, these Guidelines recom-
mended a step-wise approach, using DSCG first and
switching to inhaled corticosteroids only if DSCG failed 
to control the disease. A study by Agertoft and Pedersen
has questioned the step-wise approach and has sug-
gested that delay in starting inhaled corticosteroids could
cause irreversible airway obstruction.17 Therefore, they
suggest that inhaled corticosteroids should be the first-
line anti-inflammatory therapy. However, in this study only
prebronchodilator measurements of FEV1 were shown,
with no attempt to reverse the obstruction. Therefore the
authors could not really comment whether the obstruc-
tion was reversible or not.17
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Fig. 1 Mean percent change in forced expiratory volume in
1 s (FEV1) versus time for the allergen challenges after 1 week
of placebo (d) and 1 week of albuterol 200 m g four times daily
(s). From Cockroft DW, O’Byrne PM, Swystun VA, Bhagat R.
Regular use of inhaled albuterol and the allergen-induced late
asthmatic response. J. Allergy Clin. Immunol. 1995; 96: 44–9,
with permission.
My group has performed a study on the long-term
outcome of childhood asthma,18 in patients treated
according to the International Pediatric Guidelines.16 The
follow-up period was 8.4 years (range 2–16 years),
longer than the follow-up in the Agertoft and Pedersen
study (3–5 years).17
The initial treatment was ‘as needed’ bronchodilators
for mild patients, DSCG for moderately severe patients
and inhaled corticosteroids for severe patients who could
not be controlled by DSCG. The patients were followed
regularly in the clinic and treatment was adjusted up, if
they got worse, or down (step-down), if they were doing
well. At the end of the follow up, approximately half of the
patients treated with DSCG or inhaled corticosteroids
improved, while only 17% of those treated with broncho-
dilators did so. We found that delay in starting DSCG had
a detrimental effect on the clinical outcome, but delay in
starting inhaled corticosteroids did not have any signifi-
cant effect. Results from pulmonary function tests in the
two groups treated with anti-inflammatory drugs (DSCG
or inhaled corticosteroids) improved during the follow up,
while they deteriorated in patients treated with bron-
chodilators (Fig. 2). Post-bronchodilator values in the
group treated with DSCG, were the highest of the three
groups and they were quite normal.
In patients treated with DSCG, there was no evidence
that in the absence of treatment with inhaled steroids 
irreversible airway obstruction occurs, as suggested by
Agertoft and Pedersen.17
Our conclusions were that the step-wise approach start-
ing with DSCG has a good long-term outcome, but the
start of DSCG treatment should occur in milder patients
than the recommendations of the First International Ped-
iatric Guidelines16 recommend (patients symptomatic more
than 3 days/week).
A cross-sectional study of Finnish schoolchildren,19
based on the same Guidelines,16 has also concluded 
that the best pulmonary function tests are obtained in the
moderately severe group treated with non-steroidal anti-
inflammatory drugs (DSCG or nedocromil sodium) and
that the start of treatment with these drugs should be
earlier than the recommendations of those Guidelines.16
A later set of Guidelines did indeed change these recom-
mendations to starting non-steroidal anti-inflammatory
drugs in patients symptomatic on more than 1 day per
week (Global Initiative for Asthma, 199520).
In deciding on the risk/benefit ratio, one would
instinctively assume that, in terms of efficacy, inhaled
corticosteroids are superior to DSCG. However, review-
ing the pediatric literature shows that this superiority is
only clear-cut in studies where the patients had severe
asthma,21–23 while in patients with mild-to-moderate
disease, three of five studies showed equal efficacy24–26
and only two studies27,28 showed superior results with
inhaled corticosteroids.
In terms of safety, DSCG has an excellent record.29
Although inhaled corticosteroids have far fewer side-
effects than systemic corticosteroids, their safety record is
not as good as that of DSCG. In addition to topical side-
effects, such as oral candidiasis, dysphonia and cough,30
inhaled corticosteroids can also have systemic side-
effects, some even at regular doses.
Regular doses of beclomethasone dipropionate (approx-
imately 400 m g/day) have been shown in numerous
early studies,31 mine included,32 not to suppress growth.
However, several later studies, with the same dose of
beclomethasone dipropionate have shown significant
growth suppression (Fig. 3).33–36
The most likely explanation of the difference between
the early studies showing no growth suppression and the
more recent studies that do show suppression with 
the same dose is that the early studies were done on
severe patients, while the more recent studies examined
mild-to-moderate patients. There are several reasons why
the severity of the disease can have an effect on the sys-
temic side-effects of inhaled corticosteroids. Generally,
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Fig. 2 Pulmonary function tests (forced vital capacity (FVC),
forced expiratory volume in 1s (FEV1), forced expiratory flow in
the middle half of the FVC (FEF25–75) at start (j) and end (h) of
follow-up and after bronchodilator use at these time points ( ).
Group A, initially treated with prn (‘as needed’) b -agonists.
Group B, initially treated with sodium cromoglycate. Group C,
initially treated with inhaled corticosteroids. Treatments at end
of follow-up were changed from initial treatment in some
patients. (Modified from König P. Evidence for benefits of early
intervention with non-steroidal drugs in asthma. Pediatr.
Pulmonol. 1997; Suppl. 15: 34–9. Copyright ©1997 Wiley-
Liss Inc.).
severe patients have more severe airway obstruction and
therefore less of the inhaled drug penetrates to the lung
and becomes bioavailable through the lungs. This has
been demonstrated in adults treated with fluticasone 
(2 mg/day), which caused greater adrenal suppression 
in mild patients than in severe patients.37
Specifically regarding growth suppression, in severe
patients inhaled corticosteroids can have two beneficial
effects on growth. First, severe patients often need short
and more prolonged courses of systemic steroids, which
have a more potent growth suppressive effect than
inhaled corticosteroids. When these patients are treated
with inhaled corticosteroids, the need for systemic
steroids disappears or greatly decreases. Second, poorly
controlled asthma in itself can cause growth suppres-
sion.38 Treatment with inhaled corticosteroids will greatly
improve control of asthma, therefore improving growth.
Thus, these two beneficial effects cancel out the negative
effect on growth and no growth suppression results. In
mild patients, there is usually no need for systemic
steroids and although control of asthma improves with
addition of inhaled corticosteroids, the improvement is
not as dramatic as in severe patients. Thus, the beneficial
effects of inhaled corticosteroids are absent or weaker
and the negative effect predominates, resulting in growth
suppression (Fig. 4).
Recently, the US Food and Drug Administration (FDA)
has requested the manufacturers of inhaled and nasal
corticosteroids to include a warning that they may slow
growth rates in children. The FDA has requested labeling
that clinical studies found a mean ‘growth velocity’
reduction of about 1 cm per year (range 0.3–1.8 cm per
year) and that the effect appears to be related to dose as
well as duration.
The fact that inhaled corticosteroids cause more 
systemic side effects in milder patients is an important
consideration, because one should be less tolerant of
side effects in mild patients than in severe ones.
Another systemic side effect with regular doses of inhaled
corticosteroids (400 m g beclomethasone dipropionate) is
adrenal suppression, especially at night.39 However, the
clinical significance of this statistically significant adrenal
suppression is not clear, because these patients do not
develop life-threatening adrenal insufficiency.
A side effect shown with regular doses of budesonide
(400 m g/day) in adults is decreased skin collagen syn-
thesis.40
In adults treated with large doses of inhaled corti-
costeroids, purpura and skin thinning have been
described.41,42
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Fig. 4 Growth suppression with inhaled corticosteroids in
severe versus mild asthma. (From König P. Evidence for benefits
of early intervention with non-steroidal drugs in asthma. Pediatr.
Pulmonol. 1997; Suppl. 15: 34–9. Copyright ©1997 Wiley-
Liss Inc.
Fig. 3 Change in height from baseline of children receiving
beclomethasone dipropionate (d) and those receiving placebo
(s). (From Doull IJM, Freezer MJ, Holgate ST. Growth of pre-
pubertal children with mild asthma treated with inhaled
beclomethasone dipropionate. Am. J. Respir. Crit. Care Med.
1995; 151: 1715–19, with permission).
Theoretically, there is also the possibility that corti-
costeroids could increase IgE synthesis. This has been
shown with oral administration43 and skin application44 of
corticosteroids, but it has not been studied with inhaled
corticosteroids. Interestingly, in a Japanese study, DSCG
has been shown in vitro to decrease IgE production.45
A note of caution that needs to be remembered 
for inhaled corticosteroids is that, in addition to dose
and specific properties of each drug, the delivery system
will also have an effect on systemic bioavailability and
therefore systemic side-effects. Thorsson and associates
have compared the same dose of budesonide (400 m g)
by two delivery systems: metered-dose inhaler (MDI)
and dry powder inhaler.46 The lung deposition with the
dry powder was about double compared with the MDI,
increasing the total systemic bioavailability by about
50%. Because of the detrimental effect on the ozone
layer, MDI driven by chlorofluorocarbons (CFC)-based
propellants are being phased out all over the world. All
inhaled corticosteroids are being switched to either
powder inhalers or MDI using hydrofluoroalkane (HFA).
Delivery to the lungs using these systems can be very dif-
ferent (in most cases increased) from the CFC-driven
MDI and therefore everything that was learned about
both efficacy and safety of inhaled corticosteroids needs
to be studied again. One cannot assume that the same
drug, in the same dose, will have the same safety profile
as with the older delivery systems.
In conclusion, because of comparable efficacy in the
milder patients and better safety, DSCG is better suited
for first-line anti-inflammatory treatment than inhaled
corticosteroids and a step-wise approach, starting with
DSCG and switching to inhaled corticosteroids only if this
fails, as recommended by the Guidelines,16,20,46 is still the
logical approach.
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